image dons

I make a donation

ACCOAST

International multicentric randomized trial aiming to assess the effect of pre-treatment duration with prasugrel (time from randomization to angiography) on outcomes of patients with non-ST-segment elevation myocardial infarction

Terminée

La Grande Journée du Coeur (13 juin 2023)
Attention : plus que quelques places restantes !

La Grande Journée du Coeur (mardi 13 juin 2023)
Les présentations sont en ligne

Colloquium "Rythme et conduction" (23 avril 2024)
Inscrivez-vous !

logo étude

objectif

Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction : From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction

date de réalisation

2009

nombre de patients

4033

nombre de centres participants

171 centers in 19 countries

type de financement

Private (Eli Lilly & Daiichi Sankyo)

Référence

NCT01015287

A Comparison of Prasugrel at the Time of Percutaneous Coronary Intervention (PCI) Or as Pretreatment At the Time of Diagnosis in Patients With Non-ST-Elevation Myocardial Infarction (NSTEMI) : The ACCOAST Study

Study Description

This trial consists of two arms. One arm is a non pre-treatment arm. Participants in this arm will receive placebo immediately after NSTEMI diagnosis and prior to the diagnostic coronary angiography. A 60 mg prasugrel loading dose will be given immediately after coronary angiography when proceeding to PCI. Subsequently, participants will receive daily maintenance doses of prasugrel until day 30. Participants who are greater than or equal to 75 years of age or who have a body weight less than 60 kilograms (kg) will receive 5 mg oral dose daily. All others will receive a 10 mg oral daily maintenance dose for 30 days.
The other arm is a pre-treatment arm where participants will receive a split loading dose regimen with 30 mg of prasugrel administered immediately after NSTEMI diagnosis and prior to diagnostic coronary angiography. The remainder of the loading dose (30 mg) will be administered when the participants are proceeding to PCI. Subsequently, participants will receive daily maintenance doses of prasugrel until day 30. Participants who are greater than or equal to 75 years of age or who have a body weight less than 60 kg will receive 5 mg oral dose daily. All others will receive a 10 mg oral daily maintenance dose for 30 days.

source clinicaltrials.gov

Publications

  • Interval From Initiation of Prasugrel to Coronary Angiography in Patients With Non-ST-Segment Elevation Myocardial Infarction
    Johanne Silvain, Tomasz Rakowski, Benoit Lattuca, Zhenyu Liu, Leonardo Bolognese, Patrick Goldstein, Christian Hamm, Jean-Francois Tanguay, Jur Ten Berg, Petr Widimsky, Debra Miller, Jean-Jacques Portal, Jean-Philippe Collet, Eric Vicaut, Gilles Montalescot, Dariusz Dudek, ACCOAST Investigators
    Publicated in Journal of the American College of Cardiology
  • Optimal timing of initiation of oral P2Y12-receptor antagonist therapy in patients with non-ST elevation acute coronary syndromes. Lessons learnt from the ACCOAST-trial
    Uwe Zeymer, Gilles Montalescot, Diego Ardissino, Leonardo Bolognese, Peter Clemmensen, Jean-Philippe Collet, Jose Lopez-Sendon, Petr Widimsky
    Publicated in European Heart Journal, Acute Cardiovascular Care
  • Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel : The ACCOAST Access Substudy
    Italo Porto, Leonardo Bolognese, Dariusz Dudek, Patrick Goldstein, Christian Hamm, Jean-François Tanguay, Jurrien Ten Berg, Petr Widimský, Nicolas Le Gall, Anthony J Zagar, LeRoy A LeNarz, Debra Miller, Gilles Montalescot, ACCOAST Investigators
    Publicated in JACC: Cardiovascular Interventions
  • Impact of prasugrel pretreatment and timing of coronary artery bypass grafting on clinical outcomes of patients with non-ST-segment elevation myocardial infarction : From the A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST-Elevation Myocardial Infarction (ACCOAST) study
    Dariusz Dudek, Artur Dziewierz, Petr Widimsky, Leonardo Bolognese, Patrick Goldstein, Christian Hamm, Jean-Francois Tanguay, LeRoy LeNarz, Debra L Miller, Eileen Brown, Jurrien Ten Berg, Gilles Montalescot, ACCOAST Investigators
    Publicated in American Heart Journal
  • Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI : the ACCOAST-PCI study
    Gilles Montalescot, Jean-Philippe Collet, Patrick Ecollan, Leonardo Bolognese, Jurrien Ten Berg, Dariusz Dudek, Christian Hamm, Petr Widimsky, Jean-François Tanguay, Patrick Goldstein, Eileen Brown, Debra L Miller, LeRoy LeNarz, Eric Vicaut, ACCOAST Investigators
    Publicated in Journal of the American College of Cardiology
  • Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes
    Gilles Montalescot, Leonardo Bolognese, Dariusz Dudek, Patrick Goldstein, Christian Hamm, Jean-Francois Tanguay, Jurrien M ten Berg, Debra L Miller, Timothy M Costigan, Jochen Goedicke, Johanne Silvain, Paolo Angioli, Jacek Legutko, Margit Niethammer, Zuzana Motovska, Joseph A Jakubowski, Guillaume Cayla, Luigi Oltrona Visconti, Eric Vicaut, Petr Widimsky, ACCOAST Investigators
    Publicated in The New England Journal of Medecine
  • A comparison of prasugrel at the time of percutaneous coronary intervention or as pretreatment at the time of diagnosis in patients with non-ST-segment elevation myocardial infarction : design and rationale for the ACCOAST study
    Gilles Montalescot, Leonardo Bolognese, Dariusz Dudek, Patrick Goldstein, Christian Hamm, Jean-Francois Tanguay, Jur ten Berg, Petr Widimsky, Junxiang Luo, Debra L Miller, Jochen Goedicke
    Publicated in American Heart Journal

Autres études

+

BIO-TAVI

En cours


Correlation between the platelet reactivity, the von Willebrand factor and bleeding and thrombotic events occuring during the year following TAVI
+

EDUC-DAI

En cours


Impact of therapeutic education on the quality of life and the anxiety of patients with a defibrillator.
+

ARCACHON

En cours


To demonstrate the non-inferiority of a strategy of simple clinical follow-up (without non-invasive stress testing) in asymptomatic CAD patients with a prior history of coronary revascularization comp...